None
Quote | Can-Fite Biopharma Ltd Sponsored ADR (NYSE:CANF)
Last: | $1.98 |
---|---|
Change Percent: | -4.17% |
Open: | $2 |
Close: | $1.98 |
High: | $2.01 |
Low: | $1.91 |
Volume: | 8,664 |
Last Trade Date Time: | 04/26/2024 03:00:00 am |
News | Can-Fite Biopharma Ltd Sponsored ADR (NYSE:CANF)
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced it published an article in the Experimental and Therapeutic Medicine Journal, titled ...
A pivotal Phase III trial for advanced liver cancer, approved by FDA & EMA and a MASH Phase IIb are enrolling patients Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address onc...
Message Board Posts | Can-Fite Biopharma Ltd Sponsored ADR (NYSE:CANF)
Subject | By | Source | When |
---|---|---|---|
Can-Fite to Present at the Emerging Growth Conference | midastouch017 | investorshub | 07/07/2023 12:12:19 PM |
$CANF Price now last up | kindness | investorshub | 07/05/2023 12:30:23 PM |
$CANF MomentumIts gaining last up | midastouch017 | investorshub | 07/02/2023 3:49:17 AM |
$CANF Price gaining | JoEy D BuLL | investorshub | 07/01/2023 12:07:54 AM |
$CANF Price gaining last trade up | midastouch017 | investorshub | 06/29/2023 2:57:59 PM |
News, Short Squeeze, Breakout and More Instantly...
Can-Fite Biopharma Ltd Sponsored ADR Company Name:
CANF Stock Symbol:
NYSE Market:
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced it published an article in the Experimental and Therapeutic Medicine Journal, titled ...
A pivotal Phase III trial for advanced liver cancer, approved by FDA & EMA and a MASH Phase IIb are enrolling patients Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address onc...
Namodenoson demonstrated anti-fibrosis, anti-steatosis and anti-inflammatory effects in former Phase IIa study Patient enrolment for Phase IIb study is ongoing in Europe and Israel Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipelin...